Abstract
Cardiac resynchronization therapy is now considered a standard therapy for patients with cardiomyopathy, heart failure, and interventricular conduction delay. Despite the demonstrated benefits in multiple large-scale trials, there is a clear nonresponder rate. This brief review will address some of the issues associated with maximizing the benefit of biventricular pacing, and whether or not advances in programming of such devices will increase the number of true responders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
